Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYNOTE-365 pembrolizumab combination therapies in metastatic castration-resistant prostate cancer
NL-OMON59100Phase 2Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Feb 2022
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of pembrolizumab, olaparib and carboplatin in metastatic castration-resistant prostate cancer (mCRPC) (10 cohorts), sponsored by Merck & Co. Primary endpoints: Percentage of participants with a decrease of at least 50% in prostate-specific antigen, Number of participants with adverse events and 2 more. Started Feb 2022; status: active, not recruiting.
02
Drugs
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NL-OMON59100.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59100.